-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Pharmaceutical Stock Market] In the early trading of January 21, the healthcare sector of Hong Kong stocks changed.
As of 10:17 on January 21, Superstar Medical Holdings rose by more than 6%, Puhua Heshun rose by more than 3%, and Qiming Medical-B rose by more than 3%.
2%.
In addition, Nuohui Health-B, Kindly Medical Equipment, and Huajian Medical have followed suit
.
Changes in the health care sector of Hong Kong stocks (Source: Pharmaceutical Network) Superstar Medical Holdings rose more than 6% Specifically, Superstar Medical Holdings opened today at HK$1.
26, the current price is HK$1.
18, the turnover is 9025.
00, and the total market value is HK$2.
751 billion
.
According to the data, Superstar Medical Holding Company is an investment holding company mainly engaged in the manufacturing and sales of medical imaging products
.
The company operates through two business segments
.
The Imaging Products segment is engaged in the manufacture and sale of color photographic paper, industrial non-destructive inspection X-ray film, and the trading of imaging equipment
.
The Medical Products and Equipment segment is engaged in the manufacture and sale of medical dry film, medical wet film and dental film and the sale of medical equipment and reagents
.
According to the 2021 Interim Report of Superstar Medical Holdings, the group expects to achieve a cumulative net profit of HK$135 million in the first half of 2021, a year-on-year increase of 117.
48%
.
Puhua Heshun rose by more than 3%.
The current price of Puhua Heshun is 0.
950 Hong Kong dollars, the turnover is 81,400, the turnover rate is 0.
01%, and the total market value is 1.
491 billion Hong Kong dollars
.
The Company is an investment holding company principally engaged in the business of developing, manufacturing and selling medical devices
.
The company operates through three business segments
.
The Infusion Sets Business segment is engaged in the manufacture and sale of infusion sets
.
The Orthopedic Implants business segment is engaged in the manufacture and sale of orthopedic implant products, including trauma, spine and joint products
.
The Regenerative Medical Biomaterials Business segment is engaged in the manufacture and sale of regenerative medical biomaterial products
.
In the news, Puhua Heshun recently announced that the company will repurchase 100,000 shares on January 20, 2022, at a repurchase price of HK$0.
93 per share, involving a capital of 93,000 yuan
.
The cumulative number of securities repurchased so far this year (since the passing of the ordinary resolution) is 100,000 shares, representing 0.
006% of the number of issued shares at the time of passing the ordinary resolution
.
According to the 2021 interim report of Puhua Heshun, the company’s accumulated net profit in the first half of 2021 was HK$916 million, a year-on-year increase of 439.
20%
.
Qiming Medical-B rose by more than 2% Qiming Medical-B is currently quoted at HK$29.
100, with a turnover of HK$11.
71 million, a turnover rate of 0.
09%, and a total market value of HK$12.
833 billion
.
Hangzhou Qiming Medical Devices Co.
, Ltd.
is a domestic transcatheter heart valve medical device enterprise
.
In 2018, the market share of the company's TAVR products in China was 79.
3%
.
It is reported that the company's products and product candidates are designed for transcatheter implantation to replace heart valves (i.
e.
TAVR, TPVR, TMVR and TTVR)
.
It is estimated in the industry that the potential market of TMVR and TTVR products is much larger than that of TAVR and TPVR products, and there is huge growth potential
.
In the news, the company recently announced that it has signed an agreement with Cardiovalve Ltd.
(Cardiovalve), a transcatheter mitral valve and tricuspid valve innovative therapy company, to acquire 100% of Cardiovalve and corresponding interests at a consideration of US$300 million.
completion of milestone events, conditional payment in installments
.
According to reports, Cardiovalve independently developed by Cardiovalve is a transcatheter interventional replacement product that can treat mitral regurgitation and tricuspid regurgitation at the same time.
Its 55mm large valve annulus design is suitable for about 95% of the patient population
.
Qiming Medical-B2021 interim report shows that the company's cumulative net profit for the year was -136 million Hong Kong dollars, a year-on-year increase of -159.
77%
.
As of 10:17 on January 21, Superstar Medical Holdings rose by more than 6%, Puhua Heshun rose by more than 3%, and Qiming Medical-B rose by more than 3%.
2%.
In addition, Nuohui Health-B, Kindly Medical Equipment, and Huajian Medical have followed suit
.
Changes in the health care sector of Hong Kong stocks (Source: Pharmaceutical Network) Superstar Medical Holdings rose more than 6% Specifically, Superstar Medical Holdings opened today at HK$1.
26, the current price is HK$1.
18, the turnover is 9025.
00, and the total market value is HK$2.
751 billion
.
According to the data, Superstar Medical Holding Company is an investment holding company mainly engaged in the manufacturing and sales of medical imaging products
.
The company operates through two business segments
.
The Imaging Products segment is engaged in the manufacture and sale of color photographic paper, industrial non-destructive inspection X-ray film, and the trading of imaging equipment
.
The Medical Products and Equipment segment is engaged in the manufacture and sale of medical dry film, medical wet film and dental film and the sale of medical equipment and reagents
.
According to the 2021 Interim Report of Superstar Medical Holdings, the group expects to achieve a cumulative net profit of HK$135 million in the first half of 2021, a year-on-year increase of 117.
48%
.
Puhua Heshun rose by more than 3%.
The current price of Puhua Heshun is 0.
950 Hong Kong dollars, the turnover is 81,400, the turnover rate is 0.
01%, and the total market value is 1.
491 billion Hong Kong dollars
.
The Company is an investment holding company principally engaged in the business of developing, manufacturing and selling medical devices
.
The company operates through three business segments
.
The Infusion Sets Business segment is engaged in the manufacture and sale of infusion sets
.
The Orthopedic Implants business segment is engaged in the manufacture and sale of orthopedic implant products, including trauma, spine and joint products
.
The Regenerative Medical Biomaterials Business segment is engaged in the manufacture and sale of regenerative medical biomaterial products
.
In the news, Puhua Heshun recently announced that the company will repurchase 100,000 shares on January 20, 2022, at a repurchase price of HK$0.
93 per share, involving a capital of 93,000 yuan
.
The cumulative number of securities repurchased so far this year (since the passing of the ordinary resolution) is 100,000 shares, representing 0.
006% of the number of issued shares at the time of passing the ordinary resolution
.
According to the 2021 interim report of Puhua Heshun, the company’s accumulated net profit in the first half of 2021 was HK$916 million, a year-on-year increase of 439.
20%
.
Qiming Medical-B rose by more than 2% Qiming Medical-B is currently quoted at HK$29.
100, with a turnover of HK$11.
71 million, a turnover rate of 0.
09%, and a total market value of HK$12.
833 billion
.
Hangzhou Qiming Medical Devices Co.
, Ltd.
is a domestic transcatheter heart valve medical device enterprise
.
In 2018, the market share of the company's TAVR products in China was 79.
3%
.
It is reported that the company's products and product candidates are designed for transcatheter implantation to replace heart valves (i.
e.
TAVR, TPVR, TMVR and TTVR)
.
It is estimated in the industry that the potential market of TMVR and TTVR products is much larger than that of TAVR and TPVR products, and there is huge growth potential
.
In the news, the company recently announced that it has signed an agreement with Cardiovalve Ltd.
(Cardiovalve), a transcatheter mitral valve and tricuspid valve innovative therapy company, to acquire 100% of Cardiovalve and corresponding interests at a consideration of US$300 million.
completion of milestone events, conditional payment in installments
.
According to reports, Cardiovalve independently developed by Cardiovalve is a transcatheter interventional replacement product that can treat mitral regurgitation and tricuspid regurgitation at the same time.
Its 55mm large valve annulus design is suitable for about 95% of the patient population
.
Qiming Medical-B2021 interim report shows that the company's cumulative net profit for the year was -136 million Hong Kong dollars, a year-on-year increase of -159.
77%
.
